Amplia (ASX:ATX) Adds Ovarian Trial with ANZGOG After Narmafotinib Hits 35% Pancreatic Response Rate
Amplia Adds Ovarian Trial After Pancreatic Success
Amplia Therapeutics (ASX:ATX) has opened a new chapter in its drug story. On 8 May, the small-cap biotech announced a partnership with the…
